A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorTianjin First Central Hospital
About this trial
This prospective, multicenter, non-interventional, observational, real-world study was designed to evaluate the safety and efficacy of an adebrelimab-based regimen in patients with advanced solid tumors.
Eligibility criteria
Qualifiers
Signed informed consent and voluntarily enrolled in this study;
Histologically or cytologically confirmed extensive-stage small cell lung cancer;
Patients with other types of advanced solid tumors confirmed by histology or cytology; patients who, based on currently available data, the investigator believes may benefit from adebrelimab treatment may also be considered for enrollment;
Patients in Cohort 1 who experience disease progression and whose second-line treatment options, as assessed by the investigator, include adebrelimab in combination therapy may be enrolled in Cohort 2;
Disqualifiers
Women who have been confirmed to be pregnant or breastfeeding;
Patients with histologically or cytologically confirmed central nervous system tumors, urinary system tumors, reproductive system tumors, bone tumors, soft tissue sarcomas, melanomas and other skin tumors;
Patients with a history of human immunodeficiency virus (HIV) infection (i.e. HIV 1/2 antibody positive);
Patients with known allergies to adebrelimab or any of its drugs and excipients;
Trial design
Treatments tested in this trial
- Adebrelimab
Treatment groups
300 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov